9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Biomarkers, Tumor
  • Genomic Instability
  • Pancreatic Neoplasms
  • Precision Medicine

abstract

  • 9AC did not demonstrate substantial activity against 5-FU-refractory colorectal carcinoma on the schedule studied. Toxicities at the doses and schedule studied were unacceptable in this patient population. Based on their results, the authors consider it unlikely that 9AC administered as a 72-hour continuous intravenous infusion will play a major role in the treatment of colorectal carcinoma.

publication date

  • November 1997

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/(SICI)1097-0142(19971101)80:9<1727::AID-CNCR5>3.0.CO;2-B

PubMed ID

  • 9351540

Additional Document Info

start page

  • 1727

end page

  • 32

volume

  • 80

number

  • 9